3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Interventions
romidepsin
8
Vincristine
6
Cyclophosphamide
6
Specimen Handling
5
Rituximab
5
Biopsy
5
fludarabine
4
Prednisone
4
Methotrexate
4
Magnetic Resonance Spectroscopy
4
Lactones
4
Doxorubicin
4
Depsipeptides
4
ruxolitinib
3
duvelisib
3
belinostat
3
Nivolumab
3
Etoposide
3
Dexamethasone
3
Cytarabine
3
Calcium Dobesilate
3
Bortezomib
3
Azacitidine
3
tazemetostat
2
sodium-iodide symporter
2
pegaspargase
2
merphos
2
liposomal doxorubicin
2
cemiplimab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, T-Cell
×
tenalisib
×
Clear all
NCT02017613
2016-06-24
PI3K
Rhizen Pharmaceuticals SA
Phase 1
Completed
35 enrolled